ArticleActa pharmaceutica Sinica. B2023

Discovery of a first-in-class ANXA3 degrader for the treatment of triple-negative breast cancer.

Yongxi Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.